Dr. Ridker presents findings from the JUPITER trial, as newly released at the American Heart Association's Scientific Sessions in New Orleans.

The JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial, initiated in 2003, was designed to investigate whether rosuvastatin 20 mg compared to placebo would decrease the rate of first major cardiovascular events among apparently healthy men and women with LDL < 130 mg/dL (3.36 mmol/L) who are nonetheless at increased vascular risk on the basis of an enhanced inflammatory response, as determined by hsCRP > 2 mg/L.

In these individuals who do not currently qualify for statin therapy, rosuvastatin reduced by 47 percent incident myocardial infarction, stroke, and cardiovascular death, and significantly reduced all-cause mortality by 20 percent. The available data suggest that the screening and treatment strategy tested in JUPITER is likely to be cost-effective.

Copyright © 2008 E-MedHosting.com Inc.

After viewing this presentation the participant will be able to discuss:

- The rationale of the JUPITER trial
- Efficacy and safety data for rosuvastatin in individuals with low levels of LDL-C and elevated hsCRP
- Conclusions of the JUPITER steering committee